JP7314157B2 - ペオノール及びアポシニンを含む液体製剤 - Google Patents
ペオノール及びアポシニンを含む液体製剤 Download PDFInfo
- Publication number
- JP7314157B2 JP7314157B2 JP2020545869A JP2020545869A JP7314157B2 JP 7314157 B2 JP7314157 B2 JP 7314157B2 JP 2020545869 A JP2020545869 A JP 2020545869A JP 2020545869 A JP2020545869 A JP 2020545869A JP 7314157 B2 JP7314157 B2 JP 7314157B2
- Authority
- JP
- Japan
- Prior art keywords
- apocynin
- paeonol
- formulation
- excipient
- formulation according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- DFYRUELUNQRZTB-UHFFFAOYSA-N apocynin Chemical compound COC1=CC(C(C)=O)=CC=C1O DFYRUELUNQRZTB-UHFFFAOYSA-N 0.000 title claims description 154
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 title claims description 146
- 229930188866 apocynin Natural products 0.000 title claims description 73
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 title claims description 72
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 title claims description 70
- 239000012669 liquid formulation Substances 0.000 title claims description 25
- 239000000203 mixture Substances 0.000 claims description 63
- 238000009472 formulation Methods 0.000 claims description 46
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 42
- 150000001875 compounds Chemical class 0.000 claims description 33
- 239000000374 eutectic mixture Substances 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 11
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 9
- 150000002334 glycols Chemical class 0.000 claims description 7
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 7
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 5
- 125000003827 glycol group Chemical group 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- 150000005846 sugar alcohols Polymers 0.000 claims description 5
- 150000002170 ethers Chemical class 0.000 claims description 4
- 230000004770 neurodegeneration Effects 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 229940068918 polyethylene glycol 400 Drugs 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- 101001006370 Actinobacillus suis Hemolysin Proteins 0.000 description 20
- 241000196324 Embryophyta Species 0.000 description 13
- 239000002775 capsule Substances 0.000 description 11
- 239000000284 extract Substances 0.000 description 9
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 8
- 230000008018 melting Effects 0.000 description 8
- 238000002844 melting Methods 0.000 description 8
- 241001470615 Picrorhiza Species 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 231100000053 low toxicity Toxicity 0.000 description 5
- 239000003814 drug Substances 0.000 description 4
- 229930182470 glycoside Natural products 0.000 description 4
- 150000002338 glycosides Chemical class 0.000 description 4
- 239000007791 liquid phase Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 3
- VZEOJJIAYZCDPI-UHFFFAOYSA-N 1-(2-hydroxy-3-methoxyphenyl)ethanone Chemical compound COC1=CC=CC(C(C)=O)=C1O VZEOJJIAYZCDPI-UHFFFAOYSA-N 0.000 description 2
- 241000736199 Paeonia Species 0.000 description 2
- 235000006484 Paeonia officinalis Nutrition 0.000 description 2
- 240000005001 Paeonia suffruticosa Species 0.000 description 2
- 235000003889 Paeonia suffruticosa Nutrition 0.000 description 2
- 244000290333 Vanilla fragrans Species 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 150000008131 glucosides Chemical class 0.000 description 2
- 229930182489 iridoid glycoside Natural products 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- NLSMPWTZYGSAEU-CYUNEVMDSA-N (2s,3r,4s,5s,6r)-2-[7-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-3-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromenylium-5-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol;chloride Chemical compound [Cl-].C1=C(O)C(OC)=CC(C=2C(=CC=3C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)=CC(O)=CC=3[O+]=2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1 NLSMPWTZYGSAEU-CYUNEVMDSA-N 0.000 description 1
- XPHIPEXPAGCEBM-UHFFFAOYSA-N 2-methoxy-4-hydroxyacetophenone Natural products COC1=CC(O)=CC=C1C(C)=O XPHIPEXPAGCEBM-UHFFFAOYSA-N 0.000 description 1
- IRLNKOAURQPXIQ-WWWUCTDISA-N Apiopaeonoside Natural products O=C(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO[C@H]3[C@H](O)[C@@](O)(CO)CO3)O2)cc(OC)cc1 IRLNKOAURQPXIQ-WWWUCTDISA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- ZUKLFFYDSALIQW-MSUKCBDUSA-N Iridoid glycoside Chemical compound [H][C@]12CC[C@H](C(O)=O)[C@@]1([H])[C@H](OC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)OC=C2 ZUKLFFYDSALIQW-MSUKCBDUSA-N 0.000 description 1
- QSPOERJDZBVCJH-UHFFFAOYSA-N Kutkin Natural products COc1cc(ccc1OC2OC(CO)C(O)C(O)C2O)C(O)(OC)C(=O)OC=Cc3ccccc3 QSPOERJDZBVCJH-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001483116 Neopicrorhiza scrophulariiflora Species 0.000 description 1
- 244000236658 Paeonia lactiflora Species 0.000 description 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 1
- 241000124449 Paeonia obovata Species 0.000 description 1
- 241000124464 Paeonia veitchii Species 0.000 description 1
- IDZZECHGWAZTIB-NYBIBFQCSA-N Paeonolide Chemical compound COC1=CC=C(C(C)=O)C(O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]3[C@@H]([C@@H](O)[C@@H](O)CO3)O)O2)O)=C1 IDZZECHGWAZTIB-NYBIBFQCSA-N 0.000 description 1
- IDZZECHGWAZTIB-WPQJODJHSA-N Paeonolide Natural products O=C(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]3[C@@H](O)[C@H](O)[C@@H](O)CO3)O2)cc(OC)cc1 IDZZECHGWAZTIB-WPQJODJHSA-N 0.000 description 1
- AVIUTYMRHHBXPB-UXXRCYHCSA-N Paeonoside Natural products COC1=CC=C(C(C)=O)C(O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1 AVIUTYMRHHBXPB-UXXRCYHCSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 240000001745 Rheum palmatum Species 0.000 description 1
- 235000008090 Rheum palmatum Nutrition 0.000 description 1
- 241000207929 Scutellaria Species 0.000 description 1
- 240000004534 Scutellaria baicalensis Species 0.000 description 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- XSIQHIDJSCQWBB-QHJBZRDQSA-N [(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] 3-methoxy-4-[(E)-3-phenylprop-2-enoyl]oxybenzoate dihydrate Chemical compound O.O.COc1cc(ccc1OC(=O)\C=C\c1ccccc1)C(=O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O XSIQHIDJSCQWBB-QHJBZRDQSA-N 0.000 description 1
- XZGPUOQGERGURE-LUVHZPKESA-N [(2r,3s,4s,5r,6s)-6-[[(1as,1bs,2s,5ar,6s,6as)-6-hydroxy-1a-(hydroxymethyl)-2,5a,6,6a-tetrahydro-1bh-oxireno[5,6]cyclopenta[1,3-c]pyran-2-yl]oxy]-3,4,5-trihydroxyoxan-2-yl]methyl (e)-3-phenylprop-2-enoate Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@H]1OC=C[C@H]2[C@H](O)[C@@H]3O[C@@]3([C@@H]12)CO)OC(=O)\C=C\C1=CC=CC=C1 XZGPUOQGERGURE-LUVHZPKESA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- IDZZECHGWAZTIB-UHFFFAOYSA-N affinoside Natural products COC1=CC=C(C(C)=O)C(OC2C(C(O)C(O)C(COC3C(C(O)C(O)CO3)O)O2)O)=C1 IDZZECHGWAZTIB-UHFFFAOYSA-N 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000005496 eutectics Effects 0.000 description 1
- SCIGYBYAZUFDLA-YRWPAIAPSA-N globularin Natural products OC[C@H]1O[C@@H](O[C@@H]2OC=C[C@H]3[C@H](O)[C@@H]4O[C@]4(COC(=O)C=Cc5ccccc5)[C@@H]23)[C@H](O)[C@@H](O)[C@@H]1O SCIGYBYAZUFDLA-YRWPAIAPSA-N 0.000 description 1
- AVIUTYMRHHBXPB-UHFFFAOYSA-N glucopaeonol Natural products COC1=CC=C(C(C)=O)C(OC2C(C(O)C(O)C(CO)O2)O)=C1 AVIUTYMRHHBXPB-UHFFFAOYSA-N 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 150000008145 iridoid glycosides Chemical class 0.000 description 1
- XFFQVRFGLSBFON-DEFKTLOSSA-N kaempferol 3,7-di-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=C(C=3C=CC(O)=CC=3)OC2=C1 XFFQVRFGLSBFON-DEFKTLOSSA-N 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 229930194807 paeonin Natural products 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- KEUKDVIGAVVGLF-RUYHYXBRSA-N picroside I Natural products OC[C@]12O[C@H]1[C@@H]3O[C@@H](O[C@@H]4O[C@H](COC(=O)C=Cc5ccccc5)[C@@H](O)[C@H](O)[C@H]4O)C=C[C@@H]3[C@H]2O KEUKDVIGAVVGLF-RUYHYXBRSA-N 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
Description
室温で安定な液体の1000mgのAPPA製剤を製造するために、777.8mgのペオノールと222.2mgのアポシニンとを混合する。その混合物を加熱し、そして555.6mgのPEG400をその混合物を撹拌している間に加える。安定的な混合物は約3℃で一晩貯蔵された場合に凝固せず製造される。
約400mgのAPPAを含む製剤を製造するために、311.1mgのペオノールを88.9mgのアポシニンに混合する。その混合物を加熱し、そして222.2mgのPEG400をその混合物を撹拌している間に加える。これは室温で安定な0.533mLのペオノール及びアポシニンの液体製剤を生じる。これをカプセルの形状の医薬品の提供のために当該技術分野で既知の方法でソフトゲルカプセル内にカプセル化してもよい。
約800mgのAPPAを含む製剤の製造のために、622.2mgのペオノールを177.8mgのアポシニンに混合する。その混合物を加熱し、そして444.4mgのPEG400をその混合物を撹拌している間に加える。これは室温で安定な1.07mLのペオノール及びアポシニンの液体製剤を生じる。これをカプセルの形状の医薬品の提供のために当該技術分野で既知の方法でソフトゲルカプセル内にカプセル化してもよい。
Claims (22)
- 2-ヒドロキシ-4-メトキシアセトフェノン(ペオノール)及び4-ヒドロキシ-3-メトキシアセトフェノン(アポシニン)を活性化合物として含む液体製剤であって、ここでペオノールとアポシニンとの質量比が3:2から9:1である液体製剤であって、少なくとも一つの賦形剤をさらに含み、その中で活性化合物の総量と賦形剤との質量比が2:3から19:1である液体製剤であって、かつ
ここで、前記賦形剤がグリコール、多価アルコール、又はそのエステル及び/又はエーテルである液体製剤。 - 前記賦形剤がグリコールである請求項1に記載の製剤。
- 前記賦形剤がポリエチレングリコールである請求項2に記載の製剤。
- 前記賦形剤がポリエチレングリコール400である請求項3に記載の製剤。
- ペオノールとアポシニンとの質量比が80:20から77.7:22.3である請求項1~4のいずれか一項に記載の製剤。
- 活性化合物の総量と賦形剤との質量比が64:36である請求項1~5のいずれか一項に記載の製剤。
- 前記製剤が室温で安定である請求項1~6のいずれか一項に記載の製剤。
- 2-ヒドロキシ-4-メトキシアセトフェノン(ペオノール)及び4-ヒドロキシ-3-メトキシアセトフェノン(アポシニン)の共融混合物を含む請求項1~7のいずれか一項に記載の製剤。
- 活性化合物であるペオノール及びアポシニンの共融混合物を含む液体製剤であって、前記液体製剤は、少なくとも1つの賦形剤をさらに含む製剤。
- 前記賦形剤がグリコール、多価アルコール、又はそのエステル及び/又はエーテルである請求項9に記載の製剤。
- 前記賦形剤がグリコールである請求項10に記載の製剤。
- 前記賦形剤がポリエチレングリコールである請求項11に記載の製剤。
- 前記賦形剤がポリエチレングリコール400である請求項12に記載の製剤。
- 活性化合物の総量と賦形剤との質量比が2:3から19:1で、好ましくは2:3から9:1である請求項9~13のいずれか一項に記載の製剤。
- 活性化合物の総量と賦形剤との質量比が64:36である請求項9~14のいずれか一項に記載の製剤。
- ペオノールとアポシニンとの質量比が3:2から9:1である請求項9~15のいずれか一項に記載の製剤。
- ペオノールとアポシニンとの質量比が80:20から77.7:22.3である請求項9~16のいずれか一項に記載の製剤。
- 前記製剤が室温で安定である請求項9~17のいずれか一項に記載の製剤。
- 炎症性疾患の治療のための請求項1~18のいずれか一項に記載の製剤。
- 神経変性疾患の治療のための請求項1~19のいずれか一項に記載の製剤。
- (a)活性化合物であるペオノール及びアポシニンの共融混合物を形成することを含む、ペオノール及びアポシニンを含む液体製剤の製造方法。
- (b)賦形剤(例えばグリコール)を添加することをさらに含む請求項21に記載の製造方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023079234A JP2023104963A (ja) | 2017-11-23 | 2023-05-12 | ペオノール及びアポシニンを含む液体製剤 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1719464.8A GB2568698A (en) | 2017-11-23 | 2017-11-23 | Formulation |
GB1719464.8 | 2017-11-23 | ||
PCT/EP2018/082178 WO2019101842A1 (en) | 2017-11-23 | 2018-11-22 | Liquid formulation comprising paeonol and apocynin |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023079234A Division JP2023104963A (ja) | 2017-11-23 | 2023-05-12 | ペオノール及びアポシニンを含む液体製剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021504461A JP2021504461A (ja) | 2021-02-15 |
JP7314157B2 true JP7314157B2 (ja) | 2023-07-25 |
Family
ID=60950758
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020545869A Active JP7314157B2 (ja) | 2017-11-23 | 2018-11-22 | ペオノール及びアポシニンを含む液体製剤 |
JP2023079234A Pending JP2023104963A (ja) | 2017-11-23 | 2023-05-12 | ペオノール及びアポシニンを含む液体製剤 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023079234A Pending JP2023104963A (ja) | 2017-11-23 | 2023-05-12 | ペオノール及びアポシニンを含む液体製剤 |
Country Status (20)
Country | Link |
---|---|
US (2) | US11701325B2 (ja) |
EP (2) | EP3713546B1 (ja) |
JP (2) | JP7314157B2 (ja) |
KR (1) | KR20200090858A (ja) |
CN (2) | CN111372572B (ja) |
AU (2) | AU2018371165B2 (ja) |
CA (1) | CA3082945A1 (ja) |
CY (1) | CY1124986T1 (ja) |
DK (1) | DK3713546T3 (ja) |
ES (1) | ES2906761T3 (ja) |
GB (1) | GB2568698A (ja) |
HR (1) | HRP20220303T1 (ja) |
HU (1) | HUE057595T2 (ja) |
LT (1) | LT3713546T (ja) |
MX (2) | MX2020005313A (ja) |
PL (1) | PL3713546T3 (ja) |
PT (1) | PT3713546T (ja) |
RS (1) | RS62923B1 (ja) |
SI (1) | SI3713546T1 (ja) |
WO (1) | WO2019101842A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB202218160D0 (en) * | 2022-12-02 | 2023-01-18 | Akl Res & Development Ltd | Formulation |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2016887A1 (en) * | 1989-05-16 | 1990-11-16 | Henrich H. Paradies | Process for preparing optically active 2-aryl-alkanoic acids, in particular 2-aryl propionic acids |
CN100544708C (zh) * | 2004-08-18 | 2009-09-30 | 上海佰加壹医药有限公司 | 一种丹皮酚软胶囊及其制备方法 |
GB2424833B (en) * | 2005-04-08 | 2008-12-10 | Nicholas John Larkins | Anti-inflammatory formulation comprising apocyanin and paeonol |
GB2463080A (en) * | 2008-09-02 | 2010-03-03 | Nicholas John Larkins | Pharmaceutical preparation |
GB201115757D0 (en) * | 2011-09-12 | 2011-10-26 | Akl Inflammatory Ltd | Formulation for the treatment of benign prostate hyperplasia |
GB201416909D0 (en) * | 2014-09-25 | 2014-11-12 | Prosonix Ltd | Method of forming concentrated solution |
GB2547241A (en) * | 2016-02-11 | 2017-08-16 | Akl Res & Dev Ltd | Anti-inflammatory formulation |
-
2017
- 2017-11-23 GB GB1719464.8A patent/GB2568698A/en not_active Withdrawn
-
2018
- 2018-11-22 CN CN201880075175.5A patent/CN111372572B/zh active Active
- 2018-11-22 DK DK18810956.5T patent/DK3713546T3/da active
- 2018-11-22 PT PT188109565T patent/PT3713546T/pt unknown
- 2018-11-22 EP EP18810956.5A patent/EP3713546B1/en active Active
- 2018-11-22 KR KR1020207018001A patent/KR20200090858A/ko not_active Application Discontinuation
- 2018-11-22 CN CN202310468972.2A patent/CN116999417A/zh active Pending
- 2018-11-22 MX MX2020005313A patent/MX2020005313A/es unknown
- 2018-11-22 PL PL18810956T patent/PL3713546T3/pl unknown
- 2018-11-22 RS RS20220135A patent/RS62923B1/sr unknown
- 2018-11-22 US US16/765,627 patent/US11701325B2/en active Active
- 2018-11-22 CA CA3082945A patent/CA3082945A1/en active Pending
- 2018-11-22 WO PCT/EP2018/082178 patent/WO2019101842A1/en unknown
- 2018-11-22 HU HUE18810956A patent/HUE057595T2/hu unknown
- 2018-11-22 ES ES18810956T patent/ES2906761T3/es active Active
- 2018-11-22 HR HRP20220303TT patent/HRP20220303T1/hr unknown
- 2018-11-22 EP EP21209333.0A patent/EP4019005A1/en active Pending
- 2018-11-22 JP JP2020545869A patent/JP7314157B2/ja active Active
- 2018-11-22 AU AU2018371165A patent/AU2018371165B2/en active Active
- 2018-11-22 SI SI201830590T patent/SI3713546T1/sl unknown
- 2018-11-22 LT LTEPPCT/EP2018/082178T patent/LT3713546T/lt unknown
-
2020
- 2020-07-13 MX MX2022008551A patent/MX2022008551A/es unknown
-
2022
- 2022-02-10 CY CY20221100119T patent/CY1124986T1/el unknown
-
2023
- 2023-05-12 JP JP2023079234A patent/JP2023104963A/ja active Pending
- 2023-06-01 US US18/327,202 patent/US20230330017A1/en active Pending
-
2024
- 2024-05-27 AU AU2024203514A patent/AU2024203514A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
HUE057595T2 (hu) | 2022-05-28 |
WO2019101842A1 (en) | 2019-05-31 |
RS62923B1 (sr) | 2022-03-31 |
SI3713546T1 (sl) | 2022-04-29 |
US20230330017A1 (en) | 2023-10-19 |
ES2906761T3 (es) | 2022-04-20 |
MX2020005313A (es) | 2020-08-17 |
JP2021504461A (ja) | 2021-02-15 |
MX2022008551A (es) | 2022-08-10 |
CN111372572B (zh) | 2023-08-29 |
GB201719464D0 (en) | 2018-01-10 |
AU2018371165A1 (en) | 2020-05-21 |
EP4019005A1 (en) | 2022-06-29 |
CN116999417A (zh) | 2023-11-07 |
CY1124986T1 (el) | 2023-01-05 |
PT3713546T (pt) | 2022-02-02 |
AU2024203514A1 (en) | 2024-06-20 |
AU2018371165B2 (en) | 2024-02-29 |
US11701325B2 (en) | 2023-07-18 |
EP3713546B1 (en) | 2021-12-08 |
DK3713546T3 (da) | 2022-01-31 |
HRP20220303T1 (hr) | 2022-05-13 |
KR20200090858A (ko) | 2020-07-29 |
US20200297628A1 (en) | 2020-09-24 |
CA3082945A1 (en) | 2019-05-31 |
PL3713546T3 (pl) | 2022-05-02 |
EP3713546A1 (en) | 2020-09-30 |
LT3713546T (lt) | 2022-03-10 |
JP2023104963A (ja) | 2023-07-28 |
CN111372572A (zh) | 2020-07-03 |
GB2568698A (en) | 2019-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2606332T3 (es) | Formulaciones orales para la administración de butanos catecólicos incluyendo compuestos de NDGA | |
Xuan et al. | Extended release of highly water soluble isoniazid attained through cocrystallization with curcumin | |
JPH10245337A (ja) | 薬学的組成物 | |
AU2024203514A1 (en) | Liquid formulation comprising paeonol and apocynin | |
WO2012034540A1 (zh) | 抗肿瘤药物组合物 | |
WO2011071194A1 (ko) | 20-O-β-D-글루코피라노실-20(S)-프로토파낙사디올을 포함하는 고체분산체 | |
Wang et al. | Research Progress of Plant Active Ingredients in Pharmaceutical Cocrystal | |
KR100485936B1 (ko) | 진세노사이드 Rh2 및 Rg3 항암 조성물 | |
KR20010068837A (ko) | 느릅나무과에서 추출한 만소논이를 포함하는 항암제 | |
KR20190083770A (ko) | 밀크시슬을 포함하는 용출율이 향상된 간 질환 예방 및 치료용 조성물 | |
TW200946140A (en) | Stable-type Cucurbitacin medicinal liquid compositions | |
KR100379155B1 (ko) | 새로운 진통제 조성물 | |
JP2003321383A (ja) | 更年期障害治療用組成物、性ホルモン上昇用組成物 | |
KR101183384B1 (ko) | 20?O?β?D?글루코피라노실?20(S)?프로토파낙사디올을 포함하는 고체분산체 | |
US20240091244A1 (en) | Pharmaceutical compositions comprising picroside | |
RU2174836C1 (ru) | Фармацевтическая композиция, обладающая анальгезирующим действием | |
CN103933248A (zh) | 一种瑞香狼毒组分肠溶胶囊 | |
CN103893402A (zh) | 一种瑞香狼毒提取物栓剂 | |
CN103908525A (zh) | 一种瑞香狼毒提取物薄膜衣片 | |
CN103933234A (zh) | 一种瑞香狼毒提取物无糖颗粒 | |
CN103893397A (zh) | 一种瑞香狼毒提取物胃内漂浮片 | |
CN103933238A (zh) | 一种瑞香狼毒提取物糖衣片 | |
CN103933235A (zh) | 一种瑞香狼毒提取物软胶囊 | |
CN103877266A (zh) | 一种瑞香狼毒组分粉针剂 | |
CN103877269A (zh) | 一种瑞香狼毒提取物分散片 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20211101 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220913 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220914 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20221212 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230111 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230214 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230512 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230620 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230712 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7314157 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |